Yajun Zheng

This inventor holds 38 USPTO granted patents and 12 published patent applications, plus 4 CIPO patents and 15 EPO patents, primarily in Cancer Therapeutics. Top assignees: Vitae Pharmaceuticals, Inc., Boehringer Ingelheim International Gmbh, Pliant Therapeutics, Inc.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yajun Zheng. Retrieved from https://idiyas.com/inventor/yajun-zheng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 38 (Patent Applications = 12)

% Patents Active = 92.1

CIPO Patents = 4 (Patent Applications = 12)

EPO Patents = 15 (Patent Applications = 18)

Average Co-Inventor Count = 9.7

ph-index = 10

Forward Citations = 188(Granted Patents)

Location History:

Hockessin, DE (2014 - 2016)
Hockessin, DE (US) (2013 - 2023)
Foster City, CA (US) (2020 - 2024)

Company Filing History:

33 out of 85

Vitae Pharmaceuticals, Inc.

patents

5 out of 1,562

Boehringer Ingelheim International Gmbh

patents

4 out of 16

Pliant Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Cancer Treatment

Beta-Secretase Inhibitors

ROR-Gamma Inhibitors

Integrin Inhibitors

Amino Acid Compounds

Purine Derivatives

Liver X Receptor Modulators

Dihydropyrrolopyridine

Thiazolopyrrolidine

Isoindoline

Menin-MLL Interaction

Substituted Amino Acids

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12312359 - Inhibitors of the menin-MLL interaction (2025-05-27),

2. 11952376 - Substituted amino acids as integrin inhibitors (2024-04-09),

3. 11739085 - Inhibitors of the menin-MLL interaction (2023-08-29),

4. 11560376 - Amino acid compounds and methods of use (2023-01-24),

5. 11535614 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2022-12-27),

6. 11479557 - Inhibitors of the menin-MLL interaction (2022-10-25),

7. 11180494 - Substituted amino acids as integrin inhibitors (2021-11-23),

8. 10899758 - Inhibitors of the menin-MLL interaction (2021-01-26),

9. 10807980 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2020-10-20),

10. 10793564 - Amino acid compounds and methods of use (2020-10-06),

11. 10683302 - Inhibitors of the menin-MLL interaction (2020-06-16),

12. 10654884 - Purine derivatives as CD73 inhibitors for the treatment of cancer (2020-05-19),

13. 10399976 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2019-09-03),

14. 10336717 - Inhibitors of beta-secretase (2019-07-02),

15. 10144715 - Piperazine derivatives as liver X receptor modulators (2018-12-04),

Title: The Innovative Journey of Inventor Yajun Zheng

Introduction: Yajun Zheng, a talented inventor hailing from Hockessin, DE (US), has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Yajun Zheng holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovative thinking.

Career Highlights: With a background in engineering and a passion for problem-solving, Yajun Zheng has successfully developed cutting-edge solutions that have revolutionized various industries. His commitment to innovation has led to the creation of products that have improved the lives of many.

Collaborations: Throughout his career, Yajun Zheng has collaborated with leading research institutions, universities, and companies to further his inventions and bring them to market. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: Yajun Zheng's relentless pursuit of innovation and his dedication to pushing the boundaries of what is possible make him a true pioneer in the world of inventions. His impact on technology and society is profound, and his legacy will continue to inspire future generations of inventors.

Profile summary based on public USPTO records.